Compare BioSyntech Canada vs NephRx Corporation

NephRx Corporation is 29 yrs old and is based in United States.

NephRx Corporation is a biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of kidney failure/disease and diseases of the gastrointestinal tract, including mucositis, Crohn's disease and ulcerative colitis. Their portfolio of kidney and gastric growth factors is well covered by patents and patent disclosures in the United States and key countries throughout the world. The company has made progress demonstrating the efficacy of its lead product, a kidney growth factor peptide, in two animal models for acute renal failure. NephRx's second lead product, AMP-18, is a gastric growth factor that has been demonstrated in studies to repair the gastrointestinal tract of animals with ulcerative colitis, Crohn's disease, mucositis or gastric ulcers and possibly chronic wounds. NephRx is interested in the possibility of co-development relationships, by drug delivery or indication with other pharmaceutical or biotechnology companies.